Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Hyperemesis gravidarum and placental dysfunction disorders

BMC Pregnancy and Childbirthvolume 16, Article number: 374 (2016) | Download Citation

Abstract

Background

Evidence about the consequence of hyperemesis gravidarum (HG) on pregnancy outcomes is still inconclusive. In this study, we evaluated if occurrence of hyperemesis gravidarum is associated with placental dysfunction disorders and neonatal outcomes.

Methods

A prospective cohort study was conducted in a maternal and child health primary care referral center, Budi Kemuliaan Hospital and its branch, in Jakarta, Indonesia. 2252 pregnant women visiting the hospital for regular antenatal care visits from July 2012 until October 2014 were included at their first clinic visit. For women without, with mild and with severe hyperemesis, placental dysfunction disorders (gestational hypertension, preeclampsia (PE), stillbirth, miscarriage), neonatal outcomes (birth weight, small for gestational age (SGA), low birth weight (LBW), Apgar score at 5 min, gestational age at delivery) and placental outcomes (placental weight and placental-weight-to-birth-weight ratio (PW/BW ratio)) were studied.

Results

Compared to newborns of women without hyperemesis, newborns of women with severe hyperemesis had a 172 g lower birth weight in adjusted analysis (95%CI -333.26; -10.18; p = 0.04). There were no statistically significant effects on placental dysfunction disorders or other neonatal outcome measures.

Conclusions

The results of our study suggest that hyperemesis gravidarum does not seem to induce placental dysfunction disorders, but does, if severe lead to lower birth weight.

Open Peer Review reports

Background

Nausea and vomiting are common and usually benign symptoms of primarily the first trimester of pregnancy. The onset of nausea correlates with the level of human chorionic gonadotropin (hCG), which typically rises within 4 weeks after the last menstrual period, peaking at approximately 9 weeks of gestation [1]. Sixty percent of nausea cases resolve by the end of the first trimester and 91% by 20 weeks of gestation [1]. Hyperemesis gravidarum is at the severe end of the nausea spectrum and according to The International Statistical Classification of Disease and Related Health Problems (ICD-9), is defined as ‘persistent and excessive vomiting starting before the end of the 22nd week of gestation’. Hyperemesis gravidarum is clinically classified as mild or severe, depending on associated metabolic disturbances such as carbohydrate depletion, dehydration and electrolyte imbalance. Its incidence is estimated at 0.3 to 1.5% of all live births but is unevenly distributed on a global level [2–6]. Asian women, for instance are more likely to suffer from hyperemesis than Caucasian women [3, 5]. Hyperemesis greatly affects maternal well-being and quality of life [7, 8] and is among the most common reasons for pregnancy-associated hospitalization [6, 9, 10].

Relatively little is known about the etiology of hyperemesis [6]. Causal roles of sex hormones, thyroid hormones, H. pylori infections and paternal genes have been suggested, although consensus has not been reached [6, 11]. Levels of hCG are positively associated with occurrence and severity of hyperemesis complaints, as seen in multiple- or molar pregnancies [12, 13]. While benign nausea and vomiting in early pregnancy are closely related to temporarily increased hCG levels, it has been argued that in women with hyperemesis, the persistently high hCG level dysregulates normal stimulation of trophoblast migration, which consequently alters placentation [14–16]. Ultimately abnormal placentation could lead to placental dysfunction that clinically manifests as gestational hypertension, preeclampsia, as well as miscarriage, stillbirth and intra-uterine growth restriction (IUGR) [15, 17–19]. In particular, elevated hCG plasma levels in the second trimester are associated with development of these conditions [13, 20]. Thus, hyperemesis gravidarum, occurring in first and early second trimester, could be an early pregnancy indicator of a process that results in symptomatic placental dysfunction later.

There is limited evidence about the consequences of hyperemesis on maternal and offspring’s health. Two large cohort studies in Scandinavian countries showed that hyperemesis was associated with higher risk of preeclampsia, lower birth weight and shorter gestational duration [15, 21]. This was supported by several studies suggesting higher risks of low birth weight (LBW), small for gestational age (SGA), and preterm birth if mothers experienced hyperemesis [22–24]. However, another large study [25] and several smaller studies, [26, 27] did not show such associations.

Women who experience severe hyperemesis have a significantly reduced maternal caloric ‘intake’ and lose additional nutrients and electrolytes [28]. This state resembles fasting and often involves ketonuria, which is frequently tested by clinicians in women suspected of having hyperemesis [29, 30]. Previous studies have shown that placental efficiency changes in women exposed to famine. Increased placental weight in women who were pregnant during the Dutch Hungerwinter suggests that compensatory growth of the placenta can occur in situations where nutritional resources are lacking [31, 32]. The same compensation might occur in women who experience severe hyperemesis gravidarum, however evidence is lacking.

Both hyperemesis and placental dysfunction constitute substantial maternal and neonatal health threats, particularly in the low and middle income countries where health care resources are limited [33]. Therefore, further exploration of a relation between hyperemesis and such disorders is warranted.

Methods

The present study aimed to investigate the relation between hyperemesis and placental dysfunction disorders (gestational hypertension, preeclampsia, miscarriage, and stillbirth), and neonatal outcomes, including birth weight, small for gestational age (SGA), Apgar score and gestational age at delivery.

Study population

We used a prospective cohort of 2252 pregnant women in the private mother-child health Budi Kemuliaan Hospital and its branch (Budi Kemuliaan Petojo) in Jakarta, Indonesia. The hospital provides secondary care on maternal health, while its branch focuses on primary care services. Women who were recruited were, therefore, representative of the pregnant women population in an urban setting of a developing country. Pregnant women were recruited during their first regular visit for antenatal care (ANC) between July 2012 and October 2014. All women who attended clinic visits were invited and asked to sign written informed consent. Participants were examined and interviewed by midwives according to standard clinical care and followed up until delivery.

After enrolment, information regarding personal affairs, medical status and clinical information was obtained through interviews by midwives at ANC visits. This included socio-economic background of women and partners, women’s medical history (including previous surgery, medication), current pregnancy (last menstrual period (LMP), pre-pregnancy weight), obstetrical history (parity, previous morbidity during pregnancy, previous mode(s) of delivery), and family history of disease. Clinical information at each ANC visit included weight of the mother, blood pressure, temperature, occurrence of hyperemesis gravidarum, and presence of proteinuria.

Hyperemesis gravidarum exposure measurement

Hyperemesis gravidarum was diagnosed by midwives during routine ANC visits. Details about duration of complaints, weight loss, metabolic disturbances and associated hospitalization were recorded. For analysis, women were classified as those without, with mild or with severe hyperemesis gravidarum (women with >5% weight loss compared to pre-pregnancy weight). Only women with hyperemesis diagnosed in the first or second trimester were included [34].

Outcome measurements

Hypertensive disorders of pregnancy were classified by International Society for the study of Hypertension in Pregnancy (ISSHP) definitions [35]. Gestational hypertension was defined as systolic blood pressure of 140 mmHg or more and/or diastolic blood pressure of 90 mmHg or more at two occasions in a woman with no hypertension prior to 20 weeks of gestation. In women with gestational hypertension, proteinuria was defined as 2+ dipstick in random urine samples. Preeclampsia was diagnosed if women with gestational hypertension had proteinuria [36] or if there were also one or more convulsions (eclampsia) [37]. Due to the low incidence of eclampsia, we analyzed eclampsia patients combined with the preeclampsia group. Chronic hypertension was defined as blood pressure exceeding 140/90 mmHg before pregnancy or before 20 weeks gestation, [38] and only when found elevated at ≥ 2 occasions. Women who were diagnosed with gestational hypertension or preeclampsia received treatment according to the standard hospital protocols.

Miscarriage was defined as fetal loss before 23 weeks of pregnancy and/or weighing up to 500 g, and stillbirth as birth of a baby with no signs of life at or after 28 weeks of gestation [39]. Small for Gestational Age (SGA) was defined as birth weight at a particular gestational age was below the 10th percentile of United States National Reference for Fetal Growth [40]. Low Birth Weight (LBW) was a birth weight below 2500 g [41]. Apgar scores were measured at 1, 5, and 10 min after birth [42]. Reported outcome for Apgar score was the score 5 min postpartum. Prematurity was defined as birth before 37 weeks of gestation. Gestational age at delivery was calculated in days by subtracting the first day of last menstrual period (LMP) from the date of admission to delivery room/operation theatre. Confirmation of gestational age using ultrasound scan was not done since only limited women had access to this examination. Nine women with gestational duration > 46 weeks (probably due to inaccuracy of gestational age calculation), were excluded.

After birth, birth weight and placental dimensions (weight, length, and width) were measured using a standardized method by midwives. The placenta-to-birth weight ratio was calculated [28, 31]. After discharge from hospital, active follow-up was terminated. Analyses on neonatal outcomes were based on singleton live birth pregnancies, and therefore multiple pregnancies, stillbirths and miscarriages were excluded from analysis.

Confounding variables

Analyses of the associations between hyperemesis and placental dysfunction disorders were adjusted for socio-economic status (family income), second-hand smoking exposure, maternal age at delivery, gravidity, and pre-pregnancy body mass index (BMI).

Data analysis

Baseline analysis was stratified by hyperemesis diagnosis (severe/mild/no hyperemesis), and differences between groups evaluated with Chi-square, one-way-ANOVA or Kruskal-Wallis tests where appropriate. For skewed data, we reported median and interquartile range (IQR). Main results were expressed as crude and adjusted linear regression coefficients and odds ratios from logistic regression, with corresponding 95% confidence intervals and p-values in tables. All statistical analyses were run using IBM SPSS (version 22 for Mac).

Results

Study population

Of 2252 participants, 400 were diagnosed with hyperemesis gravidarum (18.9%). Of the diagnosed, 94 experienced weight loss varying from 1 to 13 kg. There were 1833 women without, 354 with mild and 46 women with severe hyperemesis (weight loss > 5%). Subject selection is shown in Fig. 1. The mean age of participants was 28.3 years, 27% were primigravida.

Fig. 1
figure1

Flowchart of subject selection

Full size image

Table 1 shows the baseline characteristics. The estimated total family income was used as a proxy of socio-economic status of the women and was categorized into 4 categories according to its distribution. We found that family income categories differed statistically significantly across women from different exposure groups. Women with hyperemesis also attended the first ANC visit earlier in gestation than women without hyperemesis.

Table 1 Baseline characteristics of pregnant women participating in our cohort by HG exposure status
Full size table

Hyperemesis gravidarum (HG) exposure and outcomes

Tables 2, 3 and 4 show associations between hyperemesis and placental dysfunction disorders, neonatal outcomes and placental measures. Mild and severe hyperemesis were not associated with placental dysfunction disorders. After adjustment, babies of women with severe hyperemesis were on average 172 g lighter at birth than unexposed babies. No associations were found for SGA and LBW offspring, or other adverse neonatal outcomes. Women with mild hyperemesis had slightly lighter placentas while women with severe hyperemesis had heavier placentas, although none were statistically significant. Likewise, placental-weight-to-birth weight ratios (PW/BW ratio) were lower with mild hyperemesis and higher with severe hyperemesis, although not statistically significant.

Table 2 Hyperemesis gravidarum severity groups and placental dysfunction disorders
Full size table
Table 3 Hyperemesis gravidarum severity groups and neonatal outcome
Full size table
Table 4 Hyperemesis gravidarum severity groups and placental measures
Full size table

Additional analyses regarding the effect of absolute and relative weight change during the early part of pregnancy were also conducted within women with hyperemesis gravidarum. However, no associations were found between early pregnancy weight change with later placental dysfunction disorders and neonatal or placental outcomes.

Discussion

This study shows that severe hyperemesis gravidarum is associated with a significant decrease in birth weight, but no associations between HG and gestational hypertension, preeclampsia or other placental dysfunction disorders were observed. No links were found between hyperemesis gravidarum and neonatal outcomes, such as SGA and LBW.

Strengths of this study comprise the prospective design and the number of included women. This allowed for assessing both first and second trimester effects of hyperemesis gravidarum on neonatal outcomes and particularly birth weight, to give an impression of effects on the placenta, and evaluate early pregnancy weight change as a possible mediator of the effects. However, given the low incidence of placental dysfunction disorders, our study may have been too small for definite inference. Of participants, 18.9% had some form of hyperemesis, which is very high, but our estimates of severe hyperemesis do fit previous reports. Notably, women were recruited from a referral institute for mother and child health, and indeed some with hyperemesis were referred earlier in pregnancy. Although the data about indication for referral was not available, we believe that specific referrals for hyperemesis, particularly those in early pregnancy, were for that complaint only, and not for some associated expectation of higher risk for adverse maternal or neonatal outcome, such that selection bias is unlikely. This was supported by our finding that hyperemetic pregnant women have comparable risks for obstetric complications as compared to women without hyperemesis, which include pre-pregnancy BMI, chronic hypertension and type 2 diabetes, and previous obstetric complications. Missing information increased with longer follow-up, but was largely due to women who were temporarily provided antenatal care services and then referred back to primary care, a routine that we consider unrelated to the association of interest. Our self-report questionnaire information may contain measurement error, but as patients were unaware of the study aim, such error was likely random.

Our results do not show that severe hyperemesis gravidarum increases the risk of placental dysfunction disorders. A link between hyperemesis gravidarum and placental dysfunction disorders was first suggested in a 1991 case-control study reporting a 1.6 times higher risk for preeclampsia in women with severe vomiting [43]. Consistent with our findings, previous studies also showed no increased risks of placenta dysfunction disorders with exposure to hyperemesis [44, 45]. The largest cohort to date with 1,155,033 pregnancies, of which 13,287 were complicated by hyperemesis leading to hospital admission, showed a slightly increased risk for preeclampsia, and a higher risk for pre-term preeclampsia when hyperemesis occurred in the second trimester [15]. It has been suggested that differences in outcome in hyperemetic pregnancies are explained by maternal characteristics such as (gestational) hypertension, (gestational) diabetes, and primiparity [46]. A general problem in comparing findings on relations between hyperemesis and placental dysfunction disorders is the lack of a widely accepted definition of ‘severe’ hyperemesis. Working criteria range from hyperemesis requiring hospitalization or vomiting with associated metabolic disturbances to classifications purely based on caregiver’s diagnosis. In this study, the presence of (maternal) weight loss of more than 5% (compared to the weight prior to diagnosis) was used as criterion to classify severity of hyperemesis. The measured relative weight loss provided a more objective cut off for hyperemesis severity which is also generalizable to all pregnant women of different weight.

We showed a (adjusted) 172 g lower birth weight in offspring of women with severe hyperemesis, which was not explained by gestational duration. This was in accordance with several previous reports [22, 46–49]. In this study, we did not find any association between hyperemesis and SGA or LBW, although these appeared more common in women with severe hyperemesis. Although exposed babies were born smaller, it appeared that their chances of passing the threshold of the 10th percentile for the gestational age (SGA) or 2500 g for birth weight (LBW) were equal to the non-exposed. This agrees with several previous reports, including the largest study on neonatal outcome to date [21, 27, 50]. Differences in exposure definition and classification of its severity may contribute to the variation of findings.

Previous research on the association between hyperemesis and placental measures is limited. In the present study, we detected no effects on placental weight and placenta-weight-to-birth weight ratio (PW/BW ratio). Women with severe hyperemesis, however, had heavier placentas and higher of PW/BW ratio, although not statistically significant. Heavier placentas and higher PW/BW ratio were previously reported, but only for female offspring [28]. Studies on famine and placental weight and PW/BW ratio suggest that with low caloric intake, the placenta compensatorily grows, probably to maintain adequate fetal nutrition [31, 32]. This might also occur with hyperemesis and, therefore, further research on the placenta is warranted; especially since there is evidence that compensatory growth of the placenta is associated with cardiovascular problems in later life [28, 51].

Further research requires clear HG definition and severity criteria. Large cohort studies will be needed to estimate relations between hyperemesis and placental dimensions, and rare outcomes, such as eclampsia and stillbirth. Conducting follow up studies of women with severe hyperemesis gravidarum will give a better insight in possible long term effects of hyperemesis on the health of children born out of hyperemetic pregnancies.

Conclusions

Hyperemesis gravidarum is an invalidating disease in early pregnancy, associated with hospitalizations, use of medication and a poorer quality of life. However, our findings do indicate no relevant impact of hyperemesis gravidarum on placental dysfunction disorders.

Abbreviations

ANC:

Antenatal care

ANOVA:

Analysis of variance

BMI:

Body mass index

hCG:

Human chorionic gonadotropin

HG:

Hyperemesis gravidarum

ICD-9:

The International Statistical Classification of Disease and Related Health Problems

IQR:

Interquartile range

ISSHP:

International Society for the study of Hypertension in Pregnancy

IUGR:

Intra-uterine growth restriction

LBW:

Low birth weight

LMP:

Last menstrual period

PE:

Preeclampsia

PW/BW ratio:

Placental-weight-to-birth-weight ratio

SGA:

Small for gestational age

References

  1. 1.

    Niebyl JR. Nausea and vomiting in pregnancy. N Engl J Med. 2010;363:1544–50.

  2. 2.

    Einarson TR, Piwko C, Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta-analysis. J Popul Ther Clin Pharmacol. 2013;20(2):e171–83.

  3. 3.

    Vikanes A, Grjibovski AM, Vangen S, Magnus P. Variations in prevalence of hyperemesis gravidarum by country of birth: a study of 900,074 pregnancies in Norway, 1967–2005. Scand J Public Health. 2008;36(2):135–42. doi: 10.1177/1403494807085189.

  4. 4.

    Jordan V, MacDonald J, Crichton S, Stone P, Ford H. The incidence of hyperemesis gravidarum is increased among Pacific Islanders living in Wellington. N Z Med J. 1995;108(1006):342–4.

  5. 5.

    Matsuo K, Ushioda N, Nagamatsu M, Kimura T. Hyperemesis gravidarum in Eastern Asian population. Gynecol Obstet Invest. 2007;64(4):213–6. doi: 10.1159/000106493.

  6. 6.

    Verberg MFG, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update. 2005;11(5):527–39. doi: 10.1093/humupd/dmi021.

  7. 7.

    McCarthy FP, Khashan AS, North RA, et al. A prospective cohort study investigating associations between hyperemesis gravidarum and cognitive, behavioural and emotional well-being in pregnancy. PLoS One. 2011;6(11):e27678. doi: 10.1371/journal.pone.0027678.

  8. 8.

    Munch S, Korst LM, Hernandez GD, Romero R, Goodwin TM. Health-related quality of life in women with nausea and vomiting of pregnancy: the importance of psychosocial context. J Perinatol. 2010;31(1):10–20. doi: 10.1038/jp.2010.54.

  9. 9.

    Bacak SJ, Callaghan WM, Dietz PM, Crouse C. Pregnancy-associated hospitalizations in the United States, 1999–2000. Am J Obstet Gynecol. 2005;192(2):592–7. doi: 10.1016/j.ajog.2004.10.638.

  10. 10.

    Gazmararian JA, Petersen R, Jamieson DJ, et al. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol. 2002;100(1):94–100.

  11. 11.

    Trogstad LIS, Stoltenberg C, Magnus P, Skjærven R, Irgens LM. Recurrence risk in hyperemesis gravidarum. BJOG. 2005;112(12):1641–5. doi: 10.1111/j.1471-0528.2005.00765.x.

  12. 12.

    Berkowitz R, Ozturk M, Goldstein D, Bernstein M, Hill L, Wands JR. Human chorionic gonadotropin and free subunits’ serum levels in patients with partial and complete hydatidiform moles. Obstet Gynecol. 1989;74(2):212–6.

  13. 13.

    Lepage N, Chitayat D, Kingdom J, Huang T. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol. 2003;188(5):1354–9.

  14. 14.

    Levine MG, Esser D. Total parenteral nutrition for the treatment of severe hyperemesis gravidarum: maternal nutritional effects and fetal outcome. Obstet Gynecol. 1988;72(1):102–7.

  15. 15.

    Bolin M, Åkerud H, Cnattingius S, Stephansson O, Wikström AK. Hyperemesis gravidarum and risks of placental dysfunction disorders: a population-based cohort study. BJOG. 2013;120(5):541–7. doi: 10.1111/1471-0528.12132.

  16. 16.

    Ismail SK, Kenny L. Review on hyperemesis gravidarum. Best Pract Res Clin Gastroenterol. 2007;21(5):755–69. doi: 10.1016/j.bpg.2007.05.008.

  17. 17.

    Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69(1):1–7. doi: 10.1095/biolreprod.102.014977.

  18. 18.

    Siddiqui N, Hladunewich M. Understanding the link between the placenta and future cardiovascular disease. Trends Cardiovasc Med. 2011;21(7):188–93. doi: 10.1016/j.tcm.2012.05.008.

  19. 19.

    Smith GCS, Fretts RC. Stillbirth. Lancet. 2007;370(9600):1715–25. doi: 10.1016/S0140-6736(07)61723-1.

  20. 20.

    Chen JZJ, Sheehan PM, Brennecke SP, Keogh RJ. Vessel remodelling, pregnancy hormones and extravillous trophoblast function. Mol Cell Endocrinol. 2012;349(2):138–44.

  21. 21.

    Vandraas KF, Vikanes AV, Vangen S, Magnus P, Stoer NC, Grjibovski AM. Hyperemesis gravidarum and birth outcomes-a population-based cohort study of 2.2 million births in the Norwegian Birth Registry. BJOG. 2013;120(13):1654–60.

  22. 22.

    Veenendaal MVE, van Abeelen AFM, Painter RC, van der Post JAM, Roseboom T. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG. 2011;118(11):1302–13.

  23. 23.

    Vlachodimitropoulou-Koumoutsea E, Gosh S, Manmatharajah B, Ray A, Igwe-Omoke N, Yoong W. Pregnancy outcomes in severe hyperemesis gravidarum in a multi-ethnic population. J Obstet Gynaecol. 2013;33(5):455–8. doi: 10.3109/01443615.2013.767788.

  24. 24.

    Hastoy A, Lien Tran P, Lakestani O, Barau G, Gerardin P, Boukerrou M. Hyperemesis gravidarum and pregnancy outcomes. J Gynecol Obs Biol Reprod. 2015;44(2):154–63.

  25. 25.

    Vikanes ÅV, Støer NC, Magnus P, Grjibovski AM. Hyperemesis gravidarum and pregnancy outcomes in the Norwegian Mother and Child Cohort - a cohort study. BMC Pregnancy Childbirth. 2013;13:169.

  26. 26.

    Kuru O, Sen S, Akbayır O, et al. Outcomes of pregnancies complicated by hyperemesis gravidarum. Arch Gynecol Obstet. 2012;285(6):1517–21. doi:10.1007/s00404-011-2176-3.

  27. 27.

    Buyukkayaci Duman N, Ozcan O, Bostanci MO. Hyperemesis gravidarum affects maternal sanity, thyroid hormones and fetal health: a prospective case control study. Arch Gynecol Obstet. 2015;292(2):307–12.

  28. 28.

    Vandraas KF, Vikanes AV, Støer NC, Vangen S, Magnus P, Grjibovski AM. Is hyperemesis gravidarum associated with placental weight and the placental weight-to-birth weight ratio? a population-based Norwegian cohort study. Placenta. 2013;34(11):990–4. http://dx.doi.org/10.1016/j.placenta.2013.08.001.

  29. 29.

    Tan PC, Jacob R, Quek KF, Omar SZ. Pregnancy outcome in hyperemesis gravidarum and the effect of laboratory clinical indicators of hyperemesis severity. J Obstet Gynaecol Res. 2007;33(4):457–64.

  30. 30.

    Niemeijer MN, Grooten IJ, Vos N, et al. Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis. Am J Obstet Gynecol. 2014;211(2):150.e1–15. doi:10.1016/j.ajog.2014.02.012.

  31. 31.

    Lumey LH. Reproductive outcomes in women prenatally exposed to undernutrition: a review of findings from the Dutch famine birth cohort. Proc Nutr Soc. 1998;57(1):129–35.

  32. 32.

    Roseboom TJ, Painter RC, De Rooij SR, et al. Effects of famine on placental size and efficiency. Placenta. 2011;32(5):395–9. doi:10.1016/j.placenta.2011.03.001.

  33. 33.

    Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Heal. 2014;2(6):323–33. doi: 10.1016/S2214-109X(14)70227-X.

  34. 34.

    Gross S, Librach C, Cecutti A. Maternal weight loss associated with hyperemesis gravidarum: a predictor of fetal outcome. Am J Obstet Gynecol. 1989;160(4):906–9.

  35. 35.

    Tranquilli A, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104. doi: 10.1016/j.preghy.2014.02.001.

  36. 36.

    Magee L, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obs Gynaecol Can. 2014;36(5):416–38.

  37. 37.

    Tuffnell DJ, Shennan AH, FRCOG, Waugh JJS, Walker JJ. The Management of severe eclampsia/preeclampsia. Royal College of Obstetricians and Gynaecologists. 2006;10(A):1-11

  38. 38.

    ACOG Practice Bulletin No. 125: Chronic hypertension in pregnancy.American College of Obstetricians and Gynecologists. Obstet Gynecol. 2012;119(2 Pt 1):396-407. doi: 10.1097/AOG.0b013e318249ff06. 

  39. 39.

    WHO Regional Strategy on Sexual and Reproductive Health. Definitions and Indicators in Family Planning Maternal and Child Health and Reproductive Health. Geneva: World Health Organization; 2001.

  40. 40.

    Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol. 1996;87(2):163–8. doi: 10.1016/0029-7844(95)00386-X.

  41. 41.

    Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bull World Health Organ. 1987;65(5):663–737.

  42. 42.

    Score TA. ACOG Committee Opinion. Number 333, May 2006 (replaces No. 174, July 1996): The Apgar score. Obstet Gynecol. 2006;107(5):1209–12.

  43. 43.

    Zhang J, Cai WW. Severe vomiting during pregnancy: antenatal correlates and fetal outcomes. Epidemiology. 1991;2(6):454–7.

  44. 44.

    Dodds L, Fell DB, Joseph KS, Allen VM, Butler B. Outcomes of pregnancies complicated by hyperemesis gravidarum. Obstet Gynecol. 2006;107(2 Pt 1):285–92. doi: 10.107/2/285.

  45. 45.

    Kuru O, Sen S, Akbayir O, et al. Outcomes of pregnancies complicated by hyperemesis gravidarum. Arch Gynecol Obstet. 2012;285(6):1517–21.

  46. 46.

    Roseboom TJ, Ravelli AC, van der Post JA, Painter RC. Maternal characteristics largely explain poor pregnancy outcome after hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2011;156(1):56–9. doi: 10.1016/j.ejogrb.2011.01.010.

  47. 47.

    Källén B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur J Obstet Gynecol Reprod Biol. 1987;26(4):291–302. doi: 10.1016/0028-2243(87)90127-4.

  48. 48.

    Chin RK, Lao TT. Low birth weight and hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 1988;28(3):179–83.

  49. 49.

    Paauw JD, Bierling S, Cook CR, Davis AT. Hyperemesis gravidarum and fetal outcome. J Parenter Enter Nutr. 2005;29(2):93–6. doi: 10.1177/014860710502900293.

  50. 50.

    Vikanes AV, Stoer NC, Magnus P, Grjibovski AM. Hyperemesis gravidarum and pregnancy outcomes in the Norwegian Mother and Child Cohort - a cohort study. BMC Pregnancy Childbirth. 2013;13:169. doi: 10.1186/1471-2393-13-169.

  51. 51.

    Perry IJ, Beevers DG, Whincup PH, Bareford D. Predictors of ratio of placental weight to fetal weight in multiethnic community. BMJ. 1995;310(6977):436–9. doi: 10.2307/29726370.

Download references

Acknowledgements

The authors gratefully acknowledge Ika Widyaningrum, Eka Irdianty, Nurulia Rachmat and Erna Rahmawati for their dedication in organizing data collection. We would like to thank all midwives in Budi Kemuliaan Hospital and Budi Kemuliaan Petojo for their contribution in this study. Finally we would like to thank all women who have participated in this study.

Funding

Not applicable.

Availability of data and materials

The authors are pleased to share the anonymized dataset upon receiving a specific request. Interested parties may contact aryisavitri@gmail.com.

Authors’ contributions

The authors contributions are as follows: HMK, AIS, JLB and CSPMU contributed to study concept and design; AIS acquired the data; HMK, AIS, JLB and CSPMU analysed, interpreted the data and drafted the manuscript; CSPMU, DA, MB and DEG, critically reviewed the manuscript for important intellectual content; HMK performed the statistical analysis. All authors read and approved the final manuscript.

Competing interest

The authors report no conflict of interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was ethically approved by the Institutional Review Board of Budi Kemuliaan Hospital. All women who agreed to participate in this study signed an informed consent form.

Author information

Author notes

    Affiliations

    1. Julius Center for Health Sciences and Primary Care, Global Health, University Medical Center Utrecht, Huispost Str. 6.131, PO Box 855500, 3508, GA, Utrecht, The Netherlands

      • Heleen M. Koudijs
      • , Ary I. Savitri
      • , Joyce L. Browne
      • , Diederick E. Grobbee
      •  & Cuno S. P. M. Uiterwaal

    2. Budi Kemuliaan Hospital, Jakarta, Indonesia

      • Dwirani Amelia
      •  & Mohammad Baharuddin

    Authors

    1. Search for Heleen M. Koudijs in:

    2. Search for Ary I. Savitri in:

    3. Search for Joyce L. Browne in:

    4. Search for Dwirani Amelia in:

    5. Search for Mohammad Baharuddin in:

    6. Search for Diederick E. Grobbee in:

    7. Search for Cuno S. P. M. Uiterwaal in:

    Corresponding author

    Correspondence to Ary I. Savitri.

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Keywords

    • Hyperemesis gravidarum
    • Offspring
    • Placental dysfunction disorders
    • Pregnancy

    BMC Pregnancy and Childbirth

    ISSN: 1471-2393

    Contact us